Content about Attention deficit hyperactivity disorder

April 25, 2013
Actavis to launch generic ADHD drug in December 2014

Actavis can launch a generic version of an attention deficit hyperactivity disorder drug made by Shire next year under an agreement between the two companies announced Thursday.

PARSAPPANY, N.J. — Actavis can launch a generic version of an attention deficit hyperactivity disorder drug made by Shire next year under an agreement between the two companies announced Thursday.

April 2, 2013
Reports: Analysis finds steep rise in ADHD diagnoses among children

More than one-tenth of school-age children and nearly one-fifth of high school boys in the United States have received a diagnosis for attention deficit hyperactivity disorder, according to published reports.

NEW YORK — More than one-tenth of school-age children and nearly one-fifth of high school boys in the United States have received a diagnosis for attention deficit hyperactivity disorder, according to published reports.

The New York Times reported that the dramatic rise in the number of children diagnosed with ADHD over the last decade could lead to concern of over-diagnosis of the condition, as well as overuse of medications to treat it. The Times based its report on an analysis of raw data from the Centers for Disease Control and Prevention.

February 15, 2013
FDA approves Teva ADHD drug

The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Teva Pharmaceutical Industries, the Israeli generic drug maker said.

JERUSALEM — The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Teva Pharmaceutical Industries, the Israeli generic drug maker said.

February 11, 2013
Shire to pay Impax $48 million in authorized generic Adderall XR case

Generic drug maker Impax Labs has settled with Shire Labs over an authorized generic version of a Shire drug for treating attention deficit hyperactivity disorder, Impax said.

HAYWARD, Calif. — Generic drug maker Impax Labs has settled with Shire Labs over an authorized generic version of a Shire drug for treating attention deficit hyperactivity disorder, Impax said.

January 23, 2013
Industry challenges egregious disease-state related claims made by Internet purveyor of supplements

The National Advertising Division on Tuesday recommended that Nature’s Answer discontinue a wide range of Internet advertising claims for “Bio-Strath,” including claims that the supplement benefits children with ADD/ADHD, pregnant women, people recovering from cancer treatments, people with dementia and people with diabetes.

NEW YORK — The National Advertising Division on Tuesday recommended that Nature’s Answer discontinue a wide range of Internet advertising claims for “Bio-Strath,” including claims that the supplement benefits children with ADD/ADHD, pregnant women, people recovering from cancer treatments, people with dementia and people with diabetes.

Nature's Answer agreed to comply. 

January 14, 2013
Pfizer announces availability of new ADHD drug

A new drug for treating attention deficit hyperactivity disorder made by Pfizer is now available, the drug maker said.

NEW YORK — A new drug for treating attention deficit hyperactivity disorder made by Pfizer is now available, the drug maker said.

Pfizer announced the availability of Quillivant XR (methylphenidate hydrochloride) extended-release oral suspension, calling it the first once-per-day, extended-release liquid formulation of methylphenidate. The Food and Drug Administration approved the drug in September 2012.

October 22, 2012
Pfizer buying ADHD drug maker

Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

NEW YORK — Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

The drug maker announced that it would buy privately owned NextWave Pharmaceuticals, which makes the extended-release ADHD drug Quillivant XR (methylphenidate hydrochloride), which the Food and Drug Administration approved last month. The drug is expected to appear in pharmacies in January 2013.

September 14, 2012
Impax, Teva settle with J&J, Alza over generic ADHD drug

Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.

HAYWARD, Calif. — Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.

Impax Labs and Teva Pharmaceuticals USA had settled a patent infringement suit with Janssen Pharmaceuticals and Alza over Concerta (methylphenidate hydrochloride) extended-release tablets in the 18-mg, 27-mg, 36-mg and 54-mg strengths.

September 12, 2012
Shire seeks new approval for ADHD drug

Drug maker Shire is seeking Food and Drug Administration approval for a new usage for a drug used to treat attention deficit hyperactivity disorder, the company said Wednesday.

PHILADELPHIA — Drug maker Shire is seeking Food and Drug Administration approval for a new usage for a drug used to treat attention deficit hyperactivity disorder, the company said Wednesday.

Shire announced that the FDA had accepted its regulatory approval application for Vyvanse (lisdexamfetamine dimesylate) capsules for maintenance treatment of ADHD in patients ages 6 to 17 years. There currently are no stimulants approved for maintenance treatment of the condition in that age group, Shire said, and the FDA said it would complete its review by April 2013.

March 19, 2012
Women use mental health drugs at higher rate than men, study finds

Women take mental health drugs at a much higher rate than men, according to a new study by one of the country's largest pharmacy benefit managers.

WASHINGTON — Women take mental health drugs at a much higher rate than men, according to a new study by one of the country's largest pharmacy benefit managers.

Medco Health Solutions released results of the study Monday, showing that 25% of women use psychotropic drugs, compared with 15% of men. The study was based on the pharmacy claims of more than 2 million Americans and measured the use of drugs for treating depression, anxiety, attention deficit hyperactivity disorder and psychotic disorders between 2001 and 2010.

February 7, 2012
FDA approves Vyvanse for adults with ADHD

The Food and Drug Administration has approved a drug made by Shire for attention deficit hyperactivity disorder, the company said Tuesday.

PHILADELPHIA — The Food and Drug Administration has approved a drug made by Shire for attention deficit hyperactivity disorder, the company said Tuesday.

Shire announced the FDA approval of Vyvanse (lisdexamfetamine dimesylate) capsules as a maintenance treatment for adults with ADHD. The drug already was approved for use in children and was approved for treating ADHD in adults in 2008.

The company said the approval was based on a clinical trial that showed more ADHD patients controlling their symptoms with Vyvanse than with placebo.

October 17, 2011
ADHD can be diagnosed in children from age 4, physician group says

Children can be diagnosed with attention deficit hyperactivity disorder as soon as 4 years old, according to new guidelines released Sunday by the American Academy of Pediatrics.

BOSTON — Children can be diagnosed with attention deficit hyperactivity disorder as soon as 4 years old, according to new guidelines released Sunday by the American Academy of Pediatrics.

February 28, 2011
Intuniv OKed as add-on therapy to treat ADHD

The Food and Drug Administration has approved a new use for a Shire drug to treat attention deficit hyperactivity disorder, Shire said Monday.

PHILADELPHIA — The Food and Drug Administration has approved a new use for a Shire drug to treat attention deficit hyperactivity disorder, Shire said Monday.

The FDA approved Intuniv (guanfacine) as an add-on therapy for children and adolescents already taking stimulants to treat ADHD, also known as an adjunctive therapy.

The approval was based on a nine-week placebo-controlled study of the drug in which children and adolescents received it in combination with a stimulant.